REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that data from the Company’s pivotal phase 3 trial of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV) will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held from May 29 to June 2, 2009 in Orlando, Florida. APF530 is a long-acting formulation of granisetron that utilizes the Company’s proprietary Biochronomer™ drug delivery system. Under a separate release also issued today, A.P. Pharma announced that it had completed submission of a New Drug Application (NDA) for APF530 to the U.S. Food and Drug Administration (FDA).
